PPARG and Hypertension: Another study offered similar evidence by showing that a combination of low doses of PPARα (fenofibrate) and PPARγ (rosiglitazone) activators reduced the hypertension development in the model of Ang II–infused Sprague–Dawley rats (Ciuceis et al. 2007).